Summary

Overview
Global Reactive Airway Disease Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
Reactive airway disease occurs when the bronchial tubes that bring air into the lungs overreact to an irritant, swell, and cause breathing problems. Reactive airway disease is often diagnosed in young children who are showing signs of asthma.
Reactive airway disease is an asthma-like episode that develops in the absence of an allergen within 24 hours of exposure to an aerosol, gas, fumes, or vapor. Individuals who are typically labeled as having reactive airway disease generally have a history of wheezing, coughing, dyspnea, and production of sputum that can be caused by asthma.
Market Dynamics
Increasing prevalence of respiratory illness
The increasing prevalence of respiratory illness acts as a significant driver for market growth. The two most common chronic respiratory diseases are asthma and chronic obstructive pulmonary disease (COPD). These both affect the airways in the lungs which is characterized by recurrent attacks of breathlessness and wheezing due to airway narrowing.
For instance, according to the World Health Organization Report 2023, asthma affected an estimated 262 million people and caused 455,000 deaths. Also, chronic respiratory diseases were the third-leading cause of death, responsible for 4.0 million deaths with a prevalence of 454.6 million cases globally.
Additionally, according to the Asthma and Allergy Foundation of America, approximately 10.8% of adult females and 6.5% of adult males suffer from asthma. It is the most common chronic illness among kids. Approximately 4.5 million children under the age of 18 suffer from asthma.
Furthermore, significant growth drivers such as the rising clinical trials for reactive airway disease drugs, and the new product launches are expected to drive the market in the forecast period.
Side effects associated with treatment medications
The treatment medications like beclomethasone can cause congestion, body aches, congestion, difficulty in breathing, and hoarseness. Some side effects can also occur that usually do not need medical attention. Cramps, tightness of the chest, heavy bleeding, and pain or tenderness around the eyes and cheekbones are the less common side effects.
Segment Analysis
The global reactive airway disease market is segmented based on condition, treatment, distribution channel, and region.
The bronchodilators segment accounted for approximately 43.9% of the market share
The bronchodilators segment is expected to hold the largest market share over the period forecast due to the increasing number of product launches. Bronchodilators (inhalers) help in relaxing the airways. Doctors commonly prescribe bronchodilators to treat asthma and chronic obstructive pulmonary disease (COPD).
For instance, in July 2023, Teva UK launched a new GoResp Digihaler system in the United Kingdom. GoResp Digihaler is the first integrated inhaler with built-in sensors that detect and record objective data on the patient’s use and ability to use their inhaler including inspiratory flow classification.
Additionally, in July 2023, Hormosan Pharma GmbH, a wholly-owned subsidiary of the Lupin company in Germany, launched Luforbec, a pressurized metered dose inhaler in the European nation. Luforbec is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist is suitable. Hence, due to the above factors, the segment is expected to hold the largest market share.
Geographical Analysis
North America is expected to hold a significant position in the global reactive airway disease market share
North America has maintained a significant market proportion due to factors such as the rising prevalence of bronchiectasis, product approvals, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, an estimated 350,000 to 500,000 adults have bronchiectasis in the United States. The prevalence of bronchiectasis increases with age with an 8 to 10 fold difference in prevalence after the age of 60 years.
Additionally, in January 2023, Airsupra was approved in the United States for the treatment of bronchoconstriction to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global reactive airway disease market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, drug launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the reactive airway disease market is expected to be moderately affected over the forecast period.
Market Segmentation
By Condition
• Asthma
• Bronchiectasis
• Chronic obstructive pulmonary disease (COPD)
• Cystic fibrosis
By Treatment
• Bronchodilators
• Corticosteroids
o beclomethasone
o fluticasone
o budesonide
o mometasone
• Oxygen therapy
• Epinephrine injection
By Distribution Channel
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include GlaxoSmithKline Plc., Cipla Ltd, AstraZeneca Plc, Niksan Pharmaceutical, Teva Pharmaceutical Industries Ltd., Merck KGaA, Lupin Ltd., Hikma Pharmaceuticals Plc. and Merit Pharmaceutical among others.
Key Developments
• In June 2023, Phil Inc. in partnership with Teva Pharmaceuticals launched a new program to improve access to the Digihaler family of inhalers. The goal of the program is to help enable patients to receive and refill their Digihaler medication quickly, easily, and affordably.
• In November 2023, Aurobindo Pharma received approval for Budesonide Inhalation Suspension from the U.S. FDA to market a generic medication to treat asthma in children.
Why Purchase the Report?
• To visualize the global reactive airway disease market segmentation based on condition, treatment, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global reactive airway disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global reactive airway disease market report would provide approximately 58 tables, 58 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Condition
3.2. Snippet by Treatment
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of respiratory illness
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side effects associated with treatment medications
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Condition
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
7.1.2. Market Attractiveness Index, By Condition
7.2. Asthma*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bronchiectasis
7.4. Chronic obstructive pulmonary disease (COPD)
7.5. Cystic fibrosis
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Bronchodilators*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Corticosteroids
8.3.1. beclomethasone
8.3.2. fluticasone
8.3.3. budesonide
8.3.4. mometasone
8.4. Oxygen therapy
8.5. Epinephrine injection
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Retail Pharmacy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospital Pharmacy
9.4. Online Pharmacy
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. GlaxoSmithKline Plc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Cipla Ltd
12.3. AstraZeneca Plc
12.4. Niksan Pharmaceutical
12.5. Teva Pharmaceutical Industries Ltd.
12.6. Merck KGaA
12.7. Lupin Ltd
12.8. Hikma Pharmaceuticals Plc
12.9. Merit Pharmaceutical
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us